Abstract
Basaria and Bhasin (Sept. 6 issue)1 report that men with prostate cancer who are receiving androgen-deprivation therapy have multiple adverse events. The authors included follistatin and irisin between the main targets of investigation to prevent and treat the metabolic side effects associated with androgen-deprivation therapy. It has been shown that exercise induces a marked increase in plasma and muscle follistatin and irisin.2-4 Follistatin expression changes in both the muscle and fat of diabetic rats and can be modulated by exercise.5 Concentrations of irisin increase significantly after exercise in both mice and humans, and irisin levels in the blood are correlated with irisin messenger RNA levels in muscle tissue.4 All these facts underscore the importance of exercise with regard to the overexpression of both myokines and, therefore, with regard to the prevention and treatment of sarcopenia, frailty, and the cardiometabolic complications of androgen-deprivation therapy. Although it might not be feasible for some patients, physicians should strongly recommend exercise or simple physical activity as an adjuvant therapy for patients who have prostate cancer and are receiving androgen-deprivation therapy.